Literature DB >> 35023009

Association of IL-6 promoter polymorphism hotspots (- 174G/C and - 572G/C) with cardiovascular disease risk factors.

Shams Tabrez1,2, Nasimudeen R Jabir3, Torki A Zughaibi4,5, Mohd Suhail4,5.   

Abstract

BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death globally, despite the recent advancements in clinical research. Early diagnosis of CVD and prevention of future complications are important for the management of CVD. In the present study, we determined the genotypic linkage of interleukin-6 (IL-6) promoters with the clinical, biochemical, and inflammatory markers of CVD in the Saudi population.
MATERIALS AND METHODS: The study consisted of 89 patients (male and female) with CVD who were admitted at the King Abdulaziz university hospital, Jeddah, Saudi Arabia. The biochemical parameters were evaluated using an automated chemistry analyzer, and inflammatory markers were measured using specific enzyme-linked immunosorbent assay (ELISA) kits. For genotypic analysis, Sanger sequencing was performed. We observed a statistically significant association (p < 0.05) between GG (66.29%), GC (30.34%), and CC (3.37%) genotypes at the - 174G/C (rs1800795) hotspot and neopterin levels. However, the genotypes at the - 572G/C (rs1800796) hotspot did not show any association with age, gender, obesity, diabetes, hypertension, dyslipidemia, smoking, and coronary artery status. In addition, no significant association was observed with biochemical and inflammatory markers, namely fasting blood sugar, glycated hemoglobin A1c, creatinine, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, IL-6, and C-reactive protein. The comparison between different possible genotypic groups and CVD risk factors showed a statistically significant (p < 0.05) association between the male gender and HDL with GG, rs1800795 group vs. GC, rs1800796 group. Similarly, neopterin level was also found to be significantly (p < 0.05) associated with the genotypes GC, rs1800795, and GG, rs1800796. Additionally, the male gender (p < 0.01), age (p < 0.05), serum creatinine (p < 0.001), and neopterin (p < 0.05) were found to be significantly associated with GG, rs1800795 + GG, rs1800796, GC, rs1800795 + GC, and rs1800796 GC.
CONCLUSION: The direct association of neopterin level with IL-6 promoter polymorphism at - 174G/C (rs1800795) hotspot indicated the role of inflammation in CVD pathogenesis in the Saudi population.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Cardiovascular disease; Genetic polymorphism; Interleukin-6; Neopterin

Mesh:

Substances:

Year:  2022        PMID: 35023009     DOI: 10.1007/s11033-021-07048-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  5 in total

Review 1.  The Role of Cytokines in the Development of Atherosclerosis.

Authors:  A R Fatkhullina; I O Peshkova; E K Koltsova
Journal:  Biochemistry (Mosc)       Date:  2016-11       Impact factor: 2.487

Review 2.  Early Detection System of Vascular Disease and Its Application Prospect.

Authors:  Huan Liu; Hongyu Wang
Journal:  Biomed Res Int       Date:  2016-11-30       Impact factor: 3.411

Review 3.  Vascular Smooth Muscle Cells Contribute to Atherosclerosis Immunity.

Authors:  Desheng Hu; Changjun Yin; Shanshan Luo; Andreas J R Habenicht; Sarajo K Mohanta
Journal:  Front Immunol       Date:  2019-05-17       Impact factor: 7.561

4.  ANRIL rs1333049 C/G polymorphism and coronary artery disease in a North Indian population - Gender and age specific associations.

Authors:  Naindeep Kaur; Jagtar Singh; Sreenivas Reddy
Journal:  Genet Mol Biol       Date:  2020-03-16       Impact factor: 1.771

5.  Genetic Basis and Genotype-Phenotype Correlations in Han Chinese Patients with Idiopathic Dilated Cardiomyopathy.

Authors:  Xin-Lin Zhang; Jun Xie; Rong-Fang Lan; Li-Na Kang; Lian Wang; Wei Xu; Biao Xu
Journal:  Sci Rep       Date:  2020-02-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.